Paul Bonanos

San Francisco

Biopharma Intelligence at BioCentury

I write some, I edit some

Featured in: Favicon

biocentury.com Favicon

billboard.com

Articles

Lilly’s gain in pain via Siteone takeout: Deals Report

4 days ago | biocentury.com | Paul Bonanos

ARTICLE | DealsPlus: Grin chooses Angelini as ex-North America partner for clinical asset to treat rare neurodevelopment disorder, and more By Paul Bonanos, Director of Biopharma Intelligence, and Meredith Durkin Wolfe, Director of ResearchMultibillion-dollar licensing and M&A deals attracted some of the biggest headlines this week, as did presentations at the American Society of Clinical Oncology meeting.
$9.1B Blueprint takeout gives Sanofi a growth driver in rare disease

5 days ago | biocentury.com | Paul Bonanos

ARTICLE | DealsPaul Hudson’s ninth billion-dollar deal as CEO gives pharma approved drug for systemic mastocytosis By Paul Bonanos, Director of Biopharma IntelligenceWith its purchase of Blueprint, long considered a prime M&A target, Sanofi will gain an approved drug for a rare immunological disorder as well as a pipeline that could address a broader swath of inflammatory diseases. The French pharma is paying $129 per share, or about $9.1 billion up front, to acquire Blueprint Medicines Corp.
Wave of biopharma listings on East Asian markets: Public Equity Report

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Taysha parlays FDA update into a rarity, a follow-on financing. And more By Jeff Cranmer, Executive Editor, and Paul Bonanos, Director of Biopharma IntelligenceA flurry of new listings in Hong Kong and South Korea is energizing Asia’s public equity markets. Tuesday marked the third listing of the year on the Hong Kong stock market’s 18A biotech chapter, with Pegbio Co. Ltd.
Atlas-incubated Vima launches with $60M: Venture Report

1 week ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Grin raises cash as it strikes territorial deal with Angelini; a nine-figure round for Glycoera; and more By Paul Bonanos, Director of Biopharma IntelligenceA syndicate led by Atlas Venture launched a new start-up addressing movement disorders, while two other companies garnered nine-figure venture rounds to fuel their clinical plans.
Green shoots in Hong Kong as Jiangsu Hengrui, Mirxes list on HKSE

2 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Cellcentric, Repronovo, Fore raise venture rounds By Paul Bonanos, Director of Biopharma Intelligence, and Jeff Cranmer, Executive Editor At a time when the NASDAQ biotech IPO window is all but closed, the Hong Kong exchange is suddenly stirring, with a pair of listings this week and another poised to price Monday. Jiangsu Hengrui Pharmaceutical Co. Ltd. (Shanghai:600276; HKEX:1276) priced its Hong Kong listing this week to raise HK$9.9 billion (US$1.3 billion).
Zealand vet Hansen latest add to Augustine’s C-suite

2 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksPlus: New CFO for Freenome, Porges leaving Schroedinger By Paul Bonanos, Director of Biopharma Intelligence, and Jeff Cranmer, Executive Editor Augustine Therapeutics B.V. is continuing to build its C-suite in the wake of its €78 million ($85 million) series A round, announced in March. Its latest hire, CSO Rie Schultz Hansen, arrives from Aelin Therapeutics B.V., where she was CSO; she also spent nearly 12 years at Zealand Pharma A/S (NASDAQ:ZEAL).
In biggest licensing deal yet for a China asset, Pfizer takes rights to 3SBio’s bispecific

2 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | DealsLatest agreement in the PD-(L)1 x VEGF space has pharma paying $1.25B up front for candidate headed to Phase III in China, first U.S. trial By Paul Bonanos, Director of Biopharma IntelligenceIn the latest and largest deal between a China-based biotech and a larger biopharma for a bispecific with broad potential in oncology, Pfizer is paying 3SBio $1.25 billion up front for most global rights to a clinical therapy that targets PD-1 and VEGF to treat a range of solid tumors.
23andMe’s data find home via Regeneron takeout in bankruptcy: Deals Report

2 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | DealsPlus: Biomarin/Inozyme, GSK/Boston Pharma, Abbvie/Adarx, Novo/Septerna and more By Paul Bonanos, Director of Biopharma IntelligenceAfter weeks of concern about where 23andMe’s repository of consumer genetic data will land, Regeneron has agreed to buy the company in a bankruptcy court-supervised transaction and maintain its business. Regeneron Pharmaceuticals Inc.
Biotechs need a new guidebook to parse FDA messaging: a Perspective

3 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | Editor's CommentaryImmunitybio’s experience shows ‘yes’ today doesn’t always mean ‘yes’ tomorrow, in the new FDA By Paul Bonanos, Director of Biopharma IntelligenceAn apparent about-face by FDA that resulted in a refusal-to-file letter for Immunitybio last week is a cautionary tale for biopharmas that rely on clear communication from the agency as they make decisions, often costly ones, that affect their programs and the patients they hope to serve. If what Immunitybio Inc.
Pathos’ $365M series D to support clinical prostate cancer program: Finance Report

3 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | FinanceTen life sciences companies raise about $750M in total VC money; plus public biotechs Cytomx, Sangamo draw fresh cash By Paul Bonanos, Director of Biopharma IntelligenceLess than seven months after Pathos AI closed a $62 million series C round, an undisclosed investor group has backed the Chicago-based start-up with a $365 million series D that will support clinical testing of its prostate cancer therapy. Pathos AI Inc.